2024
Quantifying White Matter Hyperintensity and Brain Volumes in Heterogeneous Clinical and Low-Field Portable MRI
Laso P, Cerri S, Sorby-Adams A, Guo J, Mateen F, Goebl P, Wu J, Liu P, Li H, Young S, Billot B, Puonti O, Sze G, Payabavash S, DeHavenon A, Sheth K, Rosen M, Kirsch J, Strisciuglio N, Wolterink J, Eshaghi A, Barkhof F, Kimberly W, Iglesias J. Quantifying White Matter Hyperintensity and Brain Volumes in Heterogeneous Clinical and Low-Field Portable MRI. 2024, 00: 1-5. DOI: 10.1109/isbi56570.2024.10635502.Peer-Reviewed Original ResearchLow-field, Portable Magnetic Resonance Imaging to Assess Hematoma Volume in Traumatic Brain Injury Patients (P10-5.008)
Zabinska J, Yadlapalli V, Mazurek M, Parasuram N, Lalwani D, Peasley E, Gilmore E, Kim J, Omay S, Sze G, Payabvash S, Sorby-Adams A, Iglesias J, Rosen M, Kimberly W, Sheth K. Low-field, Portable Magnetic Resonance Imaging to Assess Hematoma Volume in Traumatic Brain Injury Patients (P10-5.008). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000208210.Peer-Reviewed Original Research
2021
Low-Field, Portable Magnetic Resonance Imaging at the Bedside to Assess Brain Injury in Patients with Severe COVID-19 (1349)
Mazurek M, Yuen M, Cahn B, Rosen M, Gobeske K, Gilmore E, Hwang D, Kaddouh F, Kim J, Falcone G, Petersen N, Siner J, Spudich S, Sze G, Kimberly W, Sheth K. Low-Field, Portable Magnetic Resonance Imaging at the Bedside to Assess Brain Injury in Patients with Severe COVID-19 (1349). Neurology 2021, 96 DOI: 10.1212/wnl.96.15_supplement.1349.Peer-Reviewed Original Research
2020
Deployment of Portable, Bedside, Low-field Magnetic Resonance Imaging for Evaluation of Stroke Patients (272)
Cahn B, Shah J, Dyvorne H, O’Halloran R, Poole M, Yuen M, Mazurek M, Ward A, Payabvash S, Beekman R, Brown S, Falcone G, Gobeske K, Petersen N, Jasne A, Sharma R, Schindler J, Sansing L, Gilmore E, Wira C, Matouk C, Sze G, Rosen M, Kimberly W, Sheth K. Deployment of Portable, Bedside, Low-field Magnetic Resonance Imaging for Evaluation of Stroke Patients (272). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.272.Peer-Reviewed Original Research
2017
Long Term Outcomes of IV Glyburide In Patients 70 Years of Age or Under: Subgroup Analysis from the Phase II GAMES-RP Study of Patients with Large Hemispheric Infarction (S29.008)
Sheth K, Cheung K, Elm J, Hinson H, Molyneaux B, Beslow L, Sze G, Ostwaldt A, Kimberly W. Long Term Outcomes of IV Glyburide In Patients 70 Years of Age or Under: Subgroup Analysis from the Phase II GAMES-RP Study of Patients with Large Hemispheric Infarction (S29.008). Neurology 2017, 88 DOI: 10.1212/wnl.88.16_supplement.s29.008.Peer-Reviewed Original Research
2016
GAMES (Glyburide Advantage in Malignant Edema and Stroke) RP: A Phase II Study Toward Preventing Edema After Ischemia (I11.006)
Sheth K, Elm J, Hinson H, Molyneaux B, Beslow L, Sze G, Ostwaldt A, Del Zoppo G, Simard J, Jacobson S, Kimberly W. GAMES (Glyburide Advantage in Malignant Edema and Stroke) RP: A Phase II Study Toward Preventing Edema After Ischemia (I11.006). Neurology 2016, 86 DOI: 10.1212/wnl.86.16_supplement.i11.006.Peer-Reviewed Original ResearchGAMES (Glyburide Advantage in Malignant Edema and Stroke) RP Trial: Intermediate Endpoint Analysis as Proof-Of-Concept (I11.010)
Kimberly W, Elm J, Hinson H, Molyneaux B, Beslow L, Sze G, Ostwaldt A, Del Zoppo G, Simard M, Sheth K. GAMES (Glyburide Advantage in Malignant Edema and Stroke) RP Trial: Intermediate Endpoint Analysis as Proof-Of-Concept (I11.010). Neurology 2016, 86 DOI: 10.1212/wnl.86.16_supplement.i11.010.Peer-Reviewed Original ResearchGAMES (Glyburide Advantage in Malignant Edema and Stroke) RP: A Phase II Study Toward Preventing Edema After Ischemia (S7.004)
Sheth K, Elm J, Hinson H, Molyneaux B, Beslow L, Sze G, Ostwaldt A, Del Zoppo G, Simard J, Jacobson S, Kimberly W. GAMES (Glyburide Advantage in Malignant Edema and Stroke) RP: A Phase II Study Toward Preventing Edema After Ischemia (S7.004). Neurology 2016, 86 DOI: 10.1212/wnl.86.16_supplement.s7.004.Peer-Reviewed Original ResearchGAMES (Glyburide Advantage in Malignant Edema and Stroke) RP Trial: Intermediate Endpoint Analysis as Proof-Of-Concept (S7.006)
Kimberly W, Elm J, Hinson H, Molyneaux B, Beslow L, Sze G, Ostwaldt A, Del Zoppo G, Simard M, Sheth K. GAMES (Glyburide Advantage in Malignant Edema and Stroke) RP Trial: Intermediate Endpoint Analysis as Proof-Of-Concept (S7.006). Neurology 2016, 86 DOI: 10.1212/wnl.86.16_supplement.s7.006.Peer-Reviewed Original Research